Showing results (361-370 of 386) with videos related to

Sort By:
Pageof 39
Science Translational Medicine|May 4, 2018
Arginine vasopressin in cerebrospinal fluid is a marker of sociality in nonhuman primatesKaren J Parker, Joseph P Garner, Ozge Oztan, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|January 22, 2016
South African medical schools: Current state of selection criteria and medical students' demographic profileL J van der Merwe, G J van Zyl, A St Clair Gibson, et al.
The Journal of Infectious Diseases|July 11, 2003
Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adultsPunnee Pitisuttithum, Sorachai Nitayaphan, Prasert Thongcharoen, et al.
Plos One|July 5, 2012
Associations between single nucleotide polymorphisms in iron-related genes and iron status in multiethnic populationsChristine E McLaren, Stela McLachlan, Chad P Garner, et al.
Science Translational Medicine|May 3, 2019
A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autismKaren J Parker, Ozge Oztan, Robin A Libove, et al.
Plos One|July 23, 2015
Arginine Vasopressin Is a Blood-Based Biomarker of Social Functioning in Children with AutismDean S Carson, Joseph P Garner, Shellie A Hyde, et al.
Molecular Psychiatry|October 29, 2014
Cerebrospinal fluid and plasma oxytocin concentrations are positively correlated and negatively predict anxiety in childrenD S Carson, S W Berquist, T H Trujillo, et al.
Nature Communications|July 21, 2022
Targeting retinoic acid receptor alpha-corepressor interaction activates chaperone-mediated autophagy and protects against retinal degenerationRaquel Gomez-Sintes, Qisheng Xin, Juan Ignacio Jimenez-Loygorri, et al.
BMJ Open|September 28, 2017
When is a randomised controlled trial health equity relevant? Development and validation of a conceptual frameworkJ Jull, M Whitehead, M Petticrew, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2014
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patientsAndrew P Garner, Joseph M Gozgit, Rana Anjum, et al.
Pageof 39